Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Ginkgo Bioworks Holdings, Inc.

Ticker
DNA
Sector
Industry
Report date
November 10, 2026
Valye AI Score

70

High visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings call highlights, a reported drop in Q3 losses, and active market commentary on stock performance and investor takeaways.

Recent developments:
  • Ginkgo Bioworks reported a drop in Q3 losses as detailed in recent earnings call highlights [N1][N4].
  • The Q3 2026 earnings call transcript provides detailed insights into operational and financial performance [N3].
  • Investor-focused articles outline three key takeaways for long-term investors based on recent company developments [N2].
  • The company’s stock experienced larger declines than the general market in late October 2026, reflecting market volatility [N5].
  • Market commentary discusses the company’s stock falling amid broader market upticks and provides context for investors [N7][N8].
Overview

Ginkgo Bioworks Holdings, Inc. is a publicly reporting company with detailed SEC filings including annual and quarterly reports. The company demonstrates strong liquidity and ongoing operational transparency through regular earnings calls and public disclosures. Cybersecurity risk management is actively governed at the Board level with a dedicated CISO. Legal proceedings are typical and not considered material to financial condition. Recent news coverage reflects active market interest and provides additional context on company performance and stock movements.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Ginkgo Bioworks Holdings, Inc. reported a net loss of $40.98 million and basic EPS of -$0.64 for Q3 2026. The company maintains strong liquidity with a current ratio of 4.72 and cash ratio of 5.16 as of September 30, 2026. Cybersecurity governance is overseen by the Board and a dedicated CISO. No material pending litigation is reported. Recent earnings calls and news coverage provide detailed insights into operational and financial performance [S2][S1][N1][N3].

Scenarios for DNA

Bull case model:

The company maintains strong liquidity and governance frameworks, with active investor engagement through earnings calls and transparent disclosures. Recent reductions in quarterly losses and detailed operational updates suggest ongoing efforts to improve financial performance and business execution.

Bear case model:

The company continues to report net losses and negative earnings per share, indicating ongoing challenges in achieving profitability. Market volatility and stock price declines noted in recent news highlight risks related to investor sentiment and broader market conditions. Legal and cybersecurity risks, while managed, remain potential areas of concern.

Moat:

The company’s moat is supported by its specialized expertise in biotechnology and synthetic biology, combined with governance structures for cybersecurity and risk management. Its liquidity position and ongoing investor communications contribute to operational stability. However, specific competitive advantages or proprietary technologies are not detailed in the provided disclosures.

Risks overview
Risks summary
Ongoing financial losses combined with market volatility and cybersecurity risks represent the primary challenges facing the company.
Risks details:

• Financial Losses: The company reported a net loss of $40.98 million for Q3 2026 and negative earnings per share, indicating ongoing challenges in profitability.
• Market Volatility: Recent news highlights larger stock price drops compared to the general market, reflecting sensitivity to market conditions and investor sentiment.
• Cybersecurity Risks: Despite governance and oversight, cybersecurity threats pose potential financial, legal, regulatory, and reputational risks.
• Legal Proceedings: The company faces typical legal proceedings but currently does not consider any pending litigation material to its financial condition.

FINAL FORECAST FOR DNA

Final take one line
Ginkgo Bioworks Holdings, Inc. exhibits very high visibility through detailed SEC filings and active earnings call disclosures, with strong liquidity but ongoing financial losses and market volatility risks.
Final take 12 to 24 month view

Business trends: The company continues to focus on improving operational performance and reducing losses while maintaining strong liquidity and governance frameworks.
Execution milestones: Regular quarterly earnings calls and transparent disclosures provide ongoing updates on financial results and business progress.
Key risks: Persistent net losses, stock price volatility, cybersecurity threats, and typical legal proceedings remain significant challenges.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

70
LLM visibility overview
LLM Visibility known facts
  • Ginkgo Bioworks Holdings, Inc. is a company with publicly available SEC filings including a 10-K filed on 2026-02-26 and a 10-Q filed on 2026-11-09 [S1][S2].
  • As of September 30, 2026, the company reported cash and cash equivalents of $84.5 million and current assets of $310.8 million, with current liabilities of $65.8 million, resulting in a current ratio of 4.72 and a cash ratio of 5.16, indicating strong liquidity [S2].
  • The company reported a net loss of $40.98 million for the quarter ended September 30, 2026, and basic earnings per share of -$0.64 for the same period [S2].
  • The company’s cybersecurity governance includes oversight by the Board and a Chief Information Security Officer (CISO) with public and private sector experience, with regular reporting and risk management processes in place [S1].
  • The company faces legal proceedings typical for its business but does not consider any pending litigation material to its financial condition or operations [S1].
  • Recent earnings call highlights and transcripts from November 2026 provide insights into the company’s operational performance and financial results [N1][N3].
  • Recent news coverage includes analysis of the company’s stock performance, earnings results, and investor takeaways, reflecting active market interest and transparency [N1][N2][N4][N5][N7][N8].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
  • N1
  • N3
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-02-26 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-07 | www.nasdaq.com | Ginkgo Bioworks Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/ginkgo-bioworks-q3-earnings-call-highlights
  • N2 | 2026-11-07 | www.nasdaq.com | Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/ginkgo-bioworks-3-key-takeaways-long-term-investors
  • N3 | 2026-11-06 | www.nasdaq.com | Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/ginkgo-bioworks-dna-q3-2026-earnings-call-transcript
  • N4 | 2026-11-05 | www.nasdaq.com | Ginkgo Bioworks Holdings, Inc. Q3 Loss Drops | https://www.nasdaq.com/articles/ginkgo-bioworks-holdings-inc-q3-loss-drops
  • N5 | 2026-10-29 | www.nasdaq.com | Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights | https://www.nasdaq.com/articles/ginkgo-bioworks-holdings-inc-dna-suffers-larger-drop-general-market-key-insights
  • N6 | 2026-10-29 | www.nasdaq.com | Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%. | https://www.nasdaq.com/articles/cathie-wood-buying-archer-aviation-stock-heres-what-history-says-about-following-ark-stock
  • N7 | 2026-10-20 | www.nasdaq.com | Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know | https://www.nasdaq.com/articles/ginkgo-bioworks-holdings-inc-dna-stock-falls-amid-market-uptick-what-investors-need-know-0
  • N8 | 2026-10-14 | www.nasdaq.com | Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market | https://www.nasdaq.com/articles/heres-why-ginkgo-bioworks-holdings-inc-dna-fell-more-broader-market
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine